Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.41 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364970 | 1.00 | PDE4B (0.41) | PDE4BCHRM3PDE5ATLR7WDR5 | |
| SCHEMBL1362408 | 0.96 | CHRM3 (0.43) | PDE4BCHRM3PDE5ATLR7CHRM2 | |
| SCHEMBL1362404 | 0.96 | CHRM3 (0.43) | PDE4BCHRM3PDE5ATLR7CHRM2 | |
| SCHEMBL1364109 | 0.94 | PDE4B (0.42) | PDE4BCHRM3NR3C1CHRM2CHRM1 | |
| SCHEMBL4103277 | 0.93 | PDE4B (0.42) | PDE4BCHRM3PDE5ATLR7 | |
| SCHEMBL4103281 | 0.93 | PDE4B (0.42) | PDE4BCHRM3PDE5ATLR7 | |
| SCHEMBL1363785 | 0.93 | CHRM3 (0.47) | PDE4BCHRM3NR3C1 | |
| SCHEMBL1363784 | 0.93 | CHRM3 (0.47) | PDE4BCHRM3NR3C1 | |
| SCHEMBL1364717 | 0.93 | PDE4B (0.42) | PDE4BCHRM3CHRM2CHRM1 | |
| SCHEMBL1364714 | 0.93 | PDE4B (0.42) | PDE4BCHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067408-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-11-29 | — | — | US | claimed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | claimed |
| US-8067408-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-11-29 | — | — | US | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4B, PDE4A, CHRM4 | PDE4B 1/4885CHRM3 5/4885PDE5A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.